The FDA’s Green Light Could Shine on This Biotech’s Future

Good Afternoon! 

An FDA approval for a rare and deadly transplant complication could be the breakthrough this biotech needed. With strong survival data and no direct competition, the stage may be set for a commercial inflection point.

After reviewing thousands of companies, analysts isolated the 5 Stocks Set to Double based on accelerating performance, improving fundamentals, and strong technical signals.

This newly released report breaks down why these five picks may be positioned for significant moves in the coming year.

While results cannot be guaranteed, past reports uncovered gains reaching +175%, +498%, and +673%.

Access is free until midnight.

See the Free 5 Stocks Set to Double Access Today.

*This free resource is being sent by Zacks. We identify investment resources you may choose to use in making your own decisions. Use of this resource is subject to the Zacks Terms of Service.
*Past performance is no guarantee of future results. Investing involves risk. This material does not constitute investment, legal, accounting, or tax advice. Zacks Investment Research is not a licensed dealer, broker, or investment adviser.

Wall Street rose slightly as stronger-than-expected Q3 GDP data reinforced confidence in the economy, helping sustain the seasonal “Santa Claus rally.” Despite the solid growth, traders still expect rate cuts in 2026, keeping broader market sentiment upbeat.

Intel (NASDAQ: INTC) is confronting a defining moment after reports that Nvidia has paused testing of Intel’s 18A manufacturing process. That single decision lands directly on the company’s most ambitious turnaround pillar.

The 18A node is not incremental. It is the proof point that decides whether Intel can build chips for others at the very top end, and in that context, you see why even a pause carries weight.

What a Pause Really Signals

NVIDIA is among the most demanding chip designers in the world, especially in AI and high-performance computing. When testing slows, you are not looking at rejection, but at scrutiny amplified to the extreme.

For Intel, this sharpens the execution window. Performance, yield, and reliability must align perfectly because, at this tier, you are competing with foundries that have earned trust over decades.

Credibility Is Built, Not Announced

This is not a full stop for Intel’s foundry ambitions. Work continues with other partners, and the roadmap remains intact, but in moments like this, you realize how little margin exists.

The transformation from internal chip maker to global manufacturing partner will be judged by milestones, not messaging. Here, you are watching Intel reach the phase where credibility is earned factory by factory, customer by customer, with no shortcuts left.

Vertical Aerospace (NYSE: EVTL) has crossed a structural inflection point that goes far beyond any single test flight or calendar milestone. The completion of its third full-scale prototype aircraft fundamentally changes how the program can advance toward certification.

With multiple aircraft available, you are no longer looking at a fragile, stop-start development loop. Instead, Vertical can run parallel testing, maintain momentum, and keep progress moving even when one aircraft is grounded for upgrades or inspections.

From Single Asset to Fleet Strategy

This shift moves Vertical into a fleet-based development model, something only a handful of aerospace programs can execute at this stage. One aircraft can focus on all-electric certification work, while another advances hybrid-electric integration, and you get speed without stacking risk.

The practical effect is time compression. Certification data accumulates faster, bottlenecks shrink, and engineering teams stop waiting on a single airframe to unlock the next step.

Regulatory Friction Comes Off the Table

Alongside the new aircraft, the regulatory authority expanded in a way that materially alters execution. The UK Civil Aviation Authority now allows defined flight conditions and permits to be authorized internally, meaning you remove weeks of downtime from the testing loop.

That change signals trust. When you see regulators hand over that level of responsibility, it reflects confidence in safety systems, documentation, and engineering discipline.

Most investors have never been shown this before.

Just before the Great Depression, a little-known market signal quietly began identifying historic winners—long before headlines caught on.

That same signal flagged several legendary stocks at prices that now seem impossible.

Now, with volatility rising again, it’s flashing green on three under-the-radar opportunities positioned to outperform into 2026.

Click here NOW — before it's too late.

Cintas Corporation (NASDAQ: CTAS) has launched one of the boldest consolidation plays the industrial services sector has seen, proposing a $5.2B all-cash acquisition of UniFirst Corporation (NYSE: UNF). This is not about adding revenue; it is about redesigning the economics of an entire industry.

Uniform services live or die by logistics density, and when you look at the map, you start to see why this matters. Every overlapping route is wasted cost, and once you remove duplication, you unlock margin that competitors simply cannot reach.

Routing Is the Real Moat

By combining the largest and third-largest players, Cintas would gain unmatched route density across North America. When density improves, you lower fuel burn, labor hours, fleet wear, and suddenly you are operating on a different cost curve.

Inside that math, you are not just saving money; you are hardening the business. A denser network improves service reliability, raises switching costs, and quietly pulls customers deeper into the platform.

Scale Changes the Rules

If this deal closes, smaller rivals face a tougher reality. Competing against a network that spreads fixed costs across far more stops per mile compresses margins for everyone else.

At the same time, procurement leverage improves, pricing power strengthens, and fleet optimization accelerates, all while you are watching barriers to entry rise another notch. If successful, the company does not just grow bigger; it reshapes how uniform services compete for the next decade.

👉 Click here to get our closing report to your cell for free!

Omeros Corp [OMER] $15.36 (+75.54%)

Omeros jumped after the FDA approved YARTEMLEA as the first and only treatment for TA‑TMA, supported by strong response and survival data in high‑risk patients.

Dynavax Technologies [DVAX] $15.38 (+38.19%)

Dynavax rallied after Sanofi agreed to acquire the company for $15.50 per share in cash, valuing the deal at roughly $2.2 billion and strengthening its adult‑vaccine franchise.

Agios Pharmaceuticals [AGIO] $29.17 (+18.63%)

Agios rose after the FDA approved Aqvesme as the first treatment for alpha‑ or beta‑thalassemia, expanding the company’s rare blood disease portfolio.

AST SpaceMobile [ASTS] $78.05 (-8.89%)

AST SpaceMobile reversed after strong early gains, as valuation worries resurfaced despite the successful launch of its next-gen satellite with direct-to-phone 5G capabilities.

Hycroft Mining Holding Corp [HYMC] $24.96 (-8.03%)

Hycroft slipped after a massive 200% rally over the past two weeks, as investors took profits ahead of the holidays and momentum began to fade.

Limoneira Company [LMNR] $12.90 (-6.93%)

Limoneira dropped after posting a wider quarterly loss, with revenue falling, avocado sales collapsing, and long-term debt surging to over $72 million.

A rapid acceleration in AI deployment across the U.S. is creating fresh opportunities for forward-looking investors.

A free breakdown uncovers 9 companies demonstrating measurable growth and deep alignment with this next wave of AI demand.

These aren’t speculative plays—they are firms with proven traction and expanding AI footprints.

Early movers may see the greatest advantage.

Download the Free Report

That's it for today! Please, write us back, and let us know what you think of the Closing Bell Roundup. We're always eager to hear feedback!

Thanks for reading. I'll see you at the next open! 

Best Regards,
— Adam G.
Elite Trade Club

Click here to get our daily newsletter straight to your cell for free.

P.S. Just like this newsletter, it's 100% free*, and you can stop at any time by replying STOP.